請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53678
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳青周(Ching-Chow Chen) | |
dc.contributor.author | Tzu-Tang Wei | en |
dc.contributor.author | 魏子堂 | zh_TW |
dc.date.accessioned | 2021-06-16T02:27:27Z | - |
dc.date.available | 2020-09-24 | |
dc.date.copyright | 2015-09-24 | |
dc.date.issued | 2015 | |
dc.date.submitted | 2015-08-04 | |
dc.identifier.citation | 1. Siegel R, Naishadham D, & Jemal A (2013) Cancer statistics, 2013. CA Cancer J Clin 63(1):11-30.
2. Herbst RS, Heymach JV, & Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367-1380. 3. Detterbeck FC, Boffa DJ, & Tanoue LT (2009) The new lung cancer staging system. Chest 136(1):260-271. 4. Collins LG, Haines C, Perkel R, & Enck RE (2007) Lung cancer: diagnosis and management. Am Fam Physician 75(1):56-63. 5. Mountain CF (1997) Revisions in the International System for Staging Lung Cancer. Chest 111(6):1710-1717. 6. Beckles MA, Spiro SG, Colice GL, & Rudd RM (2003) The physiologic evaluation of patients with lung cancer being considered for resectional surgery. Chest 123(1 Suppl):105S-114S. 7. Browner I & Purtell M (2009) Chemotherapy in the older patient with operable non-small cell lung cancer: neoadjuvant and adjuvant regimens. Thorac Surg Clin 19(3):377-389. 8. Pao W, Iafrate AJ, & Su Z (2011) Genetically informed lung cancer medicine. J Pathol 223(2):230-240. 9. Yao X, Panichpisal K, Kurtzman N, & Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115-124. 10. Schiller JH, et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92-98. 11. Stinchcombe TE & Socinski MA (2009) Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc 6(2):233-241. 12. Pfister DG, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2):330-353. 13. Debevec L & Debeljak A (2007) Multidisciplinary management of lung cancer. J Thorac Oncol 2(6):577. 14. Ferguson KM, et al. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11(2):507-517. 15. Olayioye MA, Neve RM, Lane HA, & Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19(13):3159-3167. 16. Baselga J & Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9(7):463-475. 17. Nicholson RI, Gee JM, & Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37 Suppl 4:S9-15. 18. Ang KK, et al. (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350-7356. 19. Maemondo M, et al. (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-2388. 20. Vermorken JB, et al. (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116-1127. 21. Van Cutsem E, et al. (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408-1417. 22. Dempke WCM, Suto T, & Reck M (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67(3):257-274. 23. Toschi L & Cappuzzo F (2007) Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 12(2):211-220. 24. Huber RM & Stratakis DF (2004) Molecular oncology--perspectives in lung cancer. Lung Cancer 45 Suppl 2:S209-213. 25. Kobayashi T, et al. (2012) A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 69(5):1241-1246. 26. Garassino MC, et al. (2013) Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 27. Lipkowitz S & Weissman AM (2011) RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis. Nat Rev Cancer 11(9):629-643. 28. Grovdal LM, Stang E, Sorkin A, & Madshus IH (2004) Direct interaction of Cbl with pTyr 1045 of the EGF receptor (EGFR) is required to sort the EGFR to lysosomes for degradation. Exp Cell Res 300(2):388-395. 29. Lo FY, Tan YH, Cheng HC, Salgia R, & Wang YC (2011) An E3 ubiquitin ligase: c-Cbl: a new therapeutic target of lung cancer. Cancer 117(23):5344-5350. 30. Ogawa S, et al. (2010) Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms. Clin Cancer Res 16(15):3825-3831. 31. Balch C, et al. (2005) New anti-cancer strategies: epigenetic therapies and biomarkers. Front Biosci 10:1897-1931. 32. Jones PA & Baylin SB (2002) The fundamental role of epigenetic events in cancer. Nat Rev Genet 3(6):415-428. 33. Acharya MR, Sparreboom A, Venitz J, & Figg WD (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol 68(4):917-932. 34. Hake SB, Xiao A, & Allis CD (2004) Linking the epigenetic 'language' of covalent histone modifications to cancer. Br J Cancer 90(4):761-769. 35. Suva ML, Riggi N, & Bernstein BE (2013) Epigenetic reprogramming in cancer. Science 339(6127):1567-1570. 36. Falkenberg KJ & Johnstone RW (2014) Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13(9):673-691. 37. Xu WS, Parmigiani RB, & Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26(37):5541-5552. 38. Glozak MA & Seto E (2007) Histone deacetylases and cancer. Oncogene 26(37):5420-5432. 39. West AC & Johnstone RW (2014) New and emerging HDAC inhibitors for cancer treatment. J Clin Invest 124(1):30-39. 40. Terzic J, Grivennikov S, Karin E, & Karin M (2010) Inflammation and colon cancer. Gastroenterology 138(6):2101-2114 e2105. 41. Greten FR, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285-296. 42. Ullman TA & Itzkowitz SH (2011) Intestinal inflammation and cancer. Gastroenterology 140(6):1807-1816. 43. Moossavi S & Bishehsari F (2012) Inflammation in sporadic colorectal cancer. Arch Iran Med 15(3):166-170. 44. Hull M & Lagergren J (2014) Obesity and colorectal cancer. Gut 63(1):205. 45. Tang J, Sharif O, Pai C, & Silverman AL (2010) Mesalamine protects against colorectal cancer in inflammatory bowel disease. Digestive diseases and sciences 55(6):1696-1703. 46. van Staa TP, Card T, Logan RF, & Leufkens HG (2005) 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut 54(11):1573-1578. 47. Thurnher M, Nussbaumer O, & Gruenbacher G (2012) Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res 18(13):3524-3531. 48. Freed-Pastor WA, et al. (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148(1-2):244-258. 49. Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3(10):721-732. 50. Yuan TL & Cantley LC (2008) PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41):5497-5510. 51. Minder CM, et al. (2012) Evidence-based use of statins for primary prevention of cardiovascular disease. Am J Med 125(5):440-446. 52. Hawk E & Viner JL (2005) Statins and cancer--beyond the 'one drug, one disease' model. N Engl J Med 352(21):2238-2239. 53. Simon MS, et al. (2012) Prospective analysis of association between use of statins or other lipid-lowering agents and colorectal cancer risk. Ann Epidemiol 22(1):17-27. 54. Poynter JN, et al. (2005) Statins and the risk of colorectal cancer. N Engl J Med 352(21):2184-2192. 55. Samadder NJ, et al. (2011) Risk of colorectal cancer in self-reported inflammatory bowel disease and modification of risk by statin and NSAID use. Cancer 117(8):1640-1648. 56. Cook NR, et al. (2005) Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 294(1):47-55. 57. Chou CW, Wu MS, Huang WC, & Chen CC (2011) HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS One 6(3):e18087. 58. Yang PM, et al. (2013) Zebularine inhibits tumorigenesis and stemness of colorectal cancer via p53-dependent endoplasmic reticulum stress. Sci Rep 3:3219. 59. Lin YC, et al. (2015) DUSP1 Expression Induced by HDAC1 Inhibition Mediates Gefitinib Sensitivity in Non-Small Cell Lung Cancers. Clin Cancer Res 21(2):428-438. 60. Chu S (2012) Transcriptional regulation by post-transcriptional modification--role of phosphorylation in Sp1 transcriptional activity. Gene 508(1):1-8. 61. Kang JM, et al. (2012) CBL enhances breast tumor formation by inhibiting tumor suppressive activity of TGF-beta signaling. Oncogene 31(50):5123-5131. 62. Pao W, et al. (2009) Integration of molecular profiling into the lung cancer clinic. Clinical cancer research : an official journal of the American Association for Cancer Research 15(17):5317-5322. 63. Sequist LV, Bell DW, Lynch TJ, & Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25(5):587-595. 64. Weihua Z, et al. (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13(5):385-393. 65. Le Roy C & Wrana JL (2005) Clathrin- and non-clathrin-mediated endocytic regulation of cell signalling. Nat Rev Mol Cell Biol 6(2):112-126. 66. Peschard P, et al. (2001) Mutation of the c-Cbl TKB domain binding site on the Met receptor tyrosine kinase converts it into a transforming protein. Mol Cell 8(5):995-1004. 67. Longva KE, et al. (2002) Ubiquitination and proteasomal activity is required for transport of the EGF receptor to inner membranes of multivesicular bodies. J Cell Biol 156(5):843-854. 68. Lai AZ, Durrant M, Zuo D, Ratcliffe CD, & Park M (2012) Met kinase-dependent loss of the E3 ligase Cbl in gastric cancer. J Biol Chem 287(11):8048-8059. 69. Dulak AM, Gubish CT, Stabile LP, Henry C, & Siegfried JM (2011) HGF-independent potentiation of EGFR action by c-Met. Oncogene 30(33):3625-3635. 70. Engelman JA, et al. (2007) MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316(5827):1039-1043. 71. Porcelli L, et al. (2012) Synthetic lethality to overcome cancer drug resistance. Curr Med Chem 19(23):3858-3873. 72. Thrower JS, Hoffman L, Rechsteiner M, & Pickart CM (2000) Recognition of the polyubiquitin proteolytic signal. EMBO J 19(1):94-102. 73. Haglund K, et al. (2003) Multiple monoubiquitination of RTKs is sufficient for their endocytosis and degradation. Nat Cell Biol 5(5):461-466. 74. Edwards A, Li J, Atadja P, Bhalla K, & Haura EB (2007) Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 6(9):2515-2524. 75. Gao YS, Hubbert CC, & Yao TP (2010) The microtubule-associated histone deacetylase 6 (HDAC6) regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation. The Journal of biological chemistry 285(15):11219-11226. 76. Deribe YL, et al. (2009) Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal 2(102):ra84. 77. Hentosh P, Yuh SH, Elson CE, & Peffley DM (2001) Sterol-independent regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in tumor cells. Mol Carcinog 32(3):154-166. 78. Notarnicola M, et al. (2004) Up-regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in left-sided human colon cancer. Anticancer Res 24(6):3837-3842. 79. Moser AR, Pitot HC, & Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247(4940):322-324. 80. Kettunen HL, Kettunen AS, & Rautonen NE (2003) Intestinal immune responses in wild-type and Apcmin/+ mouse, a model for colon cancer. Cancer Res 63(16):5136-5142. 81. Shibata H, et al. (1997) Rapid colorectal adenoma formation initiated by conditional targeting of the Apc gene. Science 278(5335):120-123. 82. Villeneuve PJ & Sundaresan RS (2009) Surgical management of colorectal lung metastasis. Clin Colon Rectal Surg 22(4):233-241. 83. Edwards MS, Chadda SD, Zhao Z, Barber BL, & Sykes DP (2012) A systematic review of treatment guidelines for metastatic colorectal cancer. Colorectal Dis 14(2):e31-47. 84. Ellis LM & Hicklin DJ (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature reviews. Cancer 8(8):579-591. 85. Huang EH & Wicha MS (2008) Colon cancer stem cells: implications for prevention and therapy. Trends Mol Med 14(11):503-509. 86. Chibaudel B, Tournigand C, Andre T, & de Gramont A (2012) Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol 4(2):75-89. 87. Meyerhardt JA & Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352(5):476-487. 88. Wong WW, Dimitroulakos J, Minden MD, & Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16(4):508-519. 89. Gan Y, Wang J, Coselli J, & Wang XL (2008) Synergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells. Biochem Biophys Res Commun 365(2):386-392. 90. Lin YC, et al. (2008) Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2. Cancer Res 68(7):2375-2383. 91. Schaefer G, et al. (2011) A two-in-one antibody against HER3 and EGFR has superior inhibitory activity compared with monospecific antibodies. Cancer Cell 20(4):472-486. 92. Hanahan D & Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646-674. 93. Cotter TG (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9(7):501-507. 94. Schlossmacher G, Stevens A, & White A (2011) Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells. J Endocrinol 211(1):17-25. 95. Eyler CE & Rich JN (2008) Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 26(17):2839-2845. 96. Pignalosa D & Durante M (2012) Overcoming resistance of cancer stem cells. Lancet Oncol 13(5):e187-188. 97. Carpentino JE, et al. (2009) Aldehyde dehydrogenase-expressing colon stem cells contribute to tumorigenesis in the transition from colitis to cancer. Cancer Res 69(20):8208-8215. 98. Kodach LL, et al. (2011) Statins augment the chemosensitivity of colorectal cancer cells inducing epigenetic reprogramming and reducing colorectal cancer cell 'stemness' via the bone morphogenetic protein pathway. Gut 60(11):1544-1553. 99. Sikandar S, et al. (2010) The class I HDAC inhibitor MGCD0103 induces cell cycle arrest and apoptosis in colon cancer initiating cells by upregulating Dickkopf-1 and non-canonical Wnt signaling. Oncotarget 1(7):596-605. 100. LaBarge MA & Bissell MJ (2008) Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 118(6):2021-2024. 101. Gagliani N, Hu B, Huber S, Elinav E, & Flavell RA (2014) The fire within: microbes inflame tumors. Cell 157(4):776-783. 102. Reddy BS, et al. (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 60(2):293-297. 103. Fisher B, et al. (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97(22):1652-1662. 104. Mizoguchi A (2012) Animal models of inflammatory bowel disease. Progress in molecular biology and translational science 105:263-320. 105. Maloy KJ & Powrie F (2011) Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature 474(7351):298-306. 106. Chen GY & Nunez G (2011) Inflammasomes in intestinal inflammation and cancer. Gastroenterology 141(6):1986-1999. 107. Blaser MJ (2014) The microbiome revolution. J Clin Invest 124(10):4162-4165. 108. Schwabe RF & Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13(11):800-812. 109. Allen-Vercoe E, Strauss J, & Chadee K (2011) Fusobacterium nucleatum: an emerging gut pathogen? Gut Microbes 2(5):294-298. 110. Kostic AD, et al. (2013) Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14(2):207-215. 111. Galdiero MR, et al. (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218(11):1402-1410. 112. Grivennikov SI, et al. (2012) Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 491(7423):254-258. 113. Nesic D, Hsu Y, & Stebbins CE (2004) Assembly and function of a bacterial genotoxin. Nature 429(6990):429-433. 114. Bernstein C, et al. (2011) Carcinogenicity of deoxycholate, a secondary bile acid. Arch Toxicol 85(8):863-871. 115. Lederberg J (2000) Infectious history. Science 288(5464):287-293. 116. Fuhrman JA (2009) Microbial community structure and its functional implications. Nature 459(7244):193-199. 117. Gauthaman K, Fong CY, & Bongso A (2009) Statins, stem cells, and cancer. J Cell Biochem 106(6):975-983. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/53678 | - |
dc.description.abstract | c-Cbl是一種E3泛素接合酶,我們的研究發現,c-Cbl蛋白高度表現於正常肺組織,但不表現於非小細胞肺癌 (NSCLC) 病患之腫瘤組織,HDAC抑制劑WJ化合物或抑制HDAC1、HDAC2、HDAC3、HDAC6,於NSCLC細胞株皆可誘導c-Cbl蛋白之表現。外送c-Cbl蛋白可降低EGFR之蛋白表現並抑制NSCLC細胞之生長。EGFR蛋白受抑制亦可減少NSCLC細胞之生長,而EGFR 之Y1045位點突變,會降低WJ抑制腫瘤生長及降解EGFR蛋白之作用。共軛焦顯微鏡之分析顯示,WJ可促進c-Cbl蛋白及EGFR蛋白的交集,原位及尾靜脈注射之肺癌動物模式中,WJ可誘導c-Cbl之蛋白表現而抑制腫瘤之生長。因此,HDAC抑制劑誘導c-Cbl蛋白之表現為治療NSCLC之新穎策略。
Statins經由抑制HMG-CoA 還原酶 (HMGR) 之活性減少膽固醇之合成,HMGR藉由促進蛋白質prenylation而促進癌症之生長。我們先前研究發現,statins之 carboxylic acid結構類似hydroxamate,可抑制組蛋白去乙醯酶 (HDAC) 之活性,許多癌症都大量表現HDAC,降低抑癌基因之表現,因此HDAC為癌症治療之標的;為進一步增強statins抑制HDAC之活性,我們設計並合成小分子化合物(JMF3086, JMF3171 and JMF3173),同時抑制HMGR及HDAC活性。最近亦有各種多重標靶HDAC抑制劑正在研究開發中。 我們發現大腸直腸癌 (CRC) 病患之HMGR活性會增加,而外加mevalonate可對抗JMF3086抑制CRC細胞生長之能力,顯示HMGR為治療CRC之新穎標靶。JMF3086可藉由caspase-dependent pathway促進CRC細胞凋亡。ChIP-on-chip分析顯示,JMF3086藉由活化NR3C1和NF-B促進細胞凋亡及調控發炎相關基因之表現,進一步發現,JMF3086調節acetyl-H3K27、CBP、HDAC1和HDAC3結合至不同基因之promoter,而調控不同基因之表現。口服JMF3086可治療azoxymethane (AOM)/dextran sulphate sodium (DSS)誘導之大腸直腸癌及ApcMin/+小鼠腫瘤之生長,並抑制大腸直腸癌之肝臟與肺臟轉移,抑制血管新生及人類大腸直腸癌幹細胞。此外,JMF3086可增強oxaliplatin在各種大腸直腸癌動物模式之治療效果,因此,此新穎之多重標靶HDAC抑制劑是具療效之先導藥物,可治療大腸直腸癌。 小鼠口服JMF3086亦可預防DSS誘導之腸炎及azoxymethane (AOM)/DSS誘導之大腸直腸癌,其預防效果更勝於lovastatin併用SAHA。JMF3086可降低發炎相關細胞激素、趨化素、COX-II及cyclin D1之表現,亦可抑制巨噬細胞和嗜中性球於大腸直腸癌腫瘤組織之浸潤,並預防癌幹細胞基因之表現,AOM/DSS鼠血漿中內毒素之增加亦受JMF3086抑制。因此,此新穎多重標靶HDAC抑制劑可預防大腸直腸癌。 | zh_TW |
dc.description.abstract | We found loss of c-Cbl, an E3 ligase, expression in non-small cell lung cancer (NSCLC) compared with its adjacent normal tissue in patient specimens. HDAC inhibition by WJ or knockdown of HDAC 1, HDAC2, HDAC3 or HDAC6 all induced c-Cbl. Ectopic expression of c-Cbl induced decreased EGFR, and inhibited growth in NSCLC cells. Knockdown of EGFR inhibited NSCLC growth, and mutation of EGFR at Y1045 decreased WJ-induced growth inhibition as well as in vivo anti-cancer effect and EGFR degradation. Time-lapse confocal analysis showed co-localization of c-Cbl and EGFR after WJ treatment. Furthermore, WJ inhibited lung tumor growth through c-Cbl induction in orthotopic and tail vein injected models. C-Cbl up-regulation induced by HDACi is a potential strategy for NSCLC treatment.
Statins lower serum cholesterol levels by inhibiting 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR), which could also be an oncotarget by regulating protein prenylation associated with cancer growth. We previously disclosed that statins containing carboxylic acid chain possess activity against histone deacetylases (HDACs) which are also attractive cancer targets. In this study, we strengthened the anti-HDAC activity of statins by designing three novel HDAC/HMGR dual inhibitors (JMF3086, JMF3171 and JMF3173). Recently, various polypharmacological molecules exhibiting dual inhibition on HDACs and other therapeutic targets have been developed. We first found that HMGR activity is increased in colorectal cancer (CRC) patients, and that the addition of mevalonate reversed JMF3086-induced inhibition of CRC cell viability, suggesting that HMGR is a novel target for CRC treatment. JMF3086 induced apoptosis in colorectal cancer cells via a caspase-dependent pathway. A genome-wide ChIP-on-chip analysis in JMF3086-treated CRC cells using anti-acetyl-H3K27 antibody was performed. Apoptosis and inflammation categorized by Gene Ontology (GO) were the most significant biological functions regulated by JMF3086. Ingenuity Pathways Analysis (IPA) analysis predicted their respective regulation by NR3C1 and NF-B. JMF3086 down-regulated inflammatory and stemness genes and up-regulated tumor suppressor genes, in which differential bindings of acetyl-H3K27, CBP, HDAC1 and HDAC3 to their promoters explained this differential effect. Oral administration of JMF3086 exerted therapeutic efficacy against AOM/DSS-induced CRC in mice and inhibited tumor progression of ApcMin/+ mice. JMF3086 also inhibited CRC metastasis to lungs or livers and angiogenesis as well as the stemness in mouse models. Furthermore, JMF3086 potentiated the efficacy of oxaliplatin in different preclinical CRC models. Our data provide compelling evidence that novel polypharmacological HDAC inhibitors-statin hydroxamates exert significant therapeutic benefits against CRC in preclinical models and are promising new drugs for CRC treatment. Oral administration of JMF3086 also prevented acute inflammation in the DSS-induced colitis mouse models. AOM/DSS-induced CRC was also attenuated by JMF3086, which showed superior protective effect than the combination of lovastatin and SAHA. It also decreased proinflammatory cytokines, chemokines, COX-II and cyclin D1 in tumor tissues as well as the infiltration of macrophages and neutrophils in tumor surrounding regions. Increased stemness factors in AOM/DSS mouse models was prevented by JMF3086. Elevated serum endotoxin level found in AOM/DSS mouse models was reduced by JMF3086. This work provides strong evidence that novel polypharmacological HDAC inhibitor JMF3086 has promising effect on the chemoprevention of CRC. | en |
dc.description.provenance | Made available in DSpace on 2021-06-16T02:27:27Z (GMT). No. of bitstreams: 1 ntu-104-D99443001-1.pdf: 7671748 bytes, checksum: 6c1b0ddaadd57dbcfda501484f40c3e8 (MD5) Previous issue date: 2015 | en |
dc.description.tableofcontents | Abbreviation 2
中文摘要 4 Abstract in English 6 Chapter I. Introduction 1.Lung cancer 10 2.Epidermal growth factor receptor (EGFR) 13 3.Epigenetics 18 4.Histone deacetylase (HDAC) and HDAC inhibitors 19 5.Colorectal cancer (CRC) 26 6.Inflammation and cancer 29 7.HMG-CoA reductase (HMGR) and HMGR inhibitors (Statins) 31 8.Experimental rationale 33 Chapter II. Materials and Methods 34 Chapter III. Induction of c-Cbl Contributes to Anti-cancer Effects of HDAC Inhibitor in Lung Cancer 47 Chapter IV. Therapeutic Efficacy of Statin Hydroxamates, Novel Dual-Inhibitors of HMG-CoA Reductase and Histone Deacetylases, against Colorectal Cancer 68 Chapter V. Chemoprevention of Colitis-induced Colorectal Carcinogenesis by Statin Hydroxamate, a Novel Dual-Inhibitor Targeting Histone Deacetylases and HMG-CoA Reductase 94 Chapter VI. Conclusion and Perspective 113 References 119 Appendix 128 Publications and Honors 149 | |
dc.language.iso | en | |
dc.title | 表觀遺傳藥物之開發 | zh_TW |
dc.title | Drugging the Epigenome | en |
dc.type | Thesis | |
dc.date.schoolyear | 103-2 | |
dc.description.degree | 博士 | |
dc.contributor.oralexamcommittee | 張文昌(Wen-Chang Chang),方俊民(Jim-Min Fang),黃偉謙(Wei-Chien Huang),吳明賢(Ming-Shiang Wu) | |
dc.subject.keyword | 表觀遺傳學,HMG-CoA還原?,去乙醯?,Statin Hydroxamates, | zh_TW |
dc.subject.keyword | Epigenetics,HMG-CoA Reductase,Histone Deacetylase,Statin Hydroxamates, | en |
dc.relation.page | 150 | |
dc.rights.note | 有償授權 | |
dc.date.accepted | 2015-08-04 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 藥理學研究所 | zh_TW |
顯示於系所單位: | 藥理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-104-1.pdf 目前未授權公開取用 | 7.49 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。